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Abstract: Nicotine dependence is characteristically a chronic and relapsing disease. Although 
75%–85% of smokers would like to quit, and one-third make at least three serious lifetime 
attempts, less than 50% of smokers succeed in stopping before the age of 60. Relevant and 
complex factors contributing to sustained cigarette consumption, and strongly implicated in 
the clinical management of smokers, are the level of nicotine dependence and psychological 
distress. In this review of the literature, these two factors will be examined in detail to show 
how they may affect smoking cessation outcome and to encourage clinicians to assess patients 
so they can offer tailored support in quitting smoking.
Keywords: nicotine dependence, psychological distress, quitting, smoking cessation, clinical 
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Introduction
In 1980, the diagnosis of “nicotine dependence” was for the first time included in the 
third edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM). 
Eight years later, the US Surgeon General published a seminal report entitled “The 
health consequences of smoking: nicotine and addiction,”1 where tobacco smoking was 
defined as an addiction. Current criteria for the diagnosis of nicotine dependence are 
defined by the American Psychiatric Association in the DSM fourth edition-text revised 
(DSM-IV-TR)2 and by the World Health Organization (WHO) in the  International 
Classification of Diseases, 10th revision (IDC-10).3
The prevalence of nicotine dependence in the general population is about 13%, con-
stituting nearly half of current nicotine users.4 Since the vast majority of smokers smoke 
for most of their life, alternating periods of remission and relapse, nicotine dependence is 
currently widely recognised as a chronic and relapsing disease.5 Although 75%–85% of 
smokers would like to stop, several attempts are usually needed before quitting definitively 
and less than 50% of smokers succeed in stopping permanently before the age of 60.6
Although pharmacological and nonpharmacological interventions are effective in 
treating nicotine dependence, there is a growing interest in identifying the factors that 
may influence smoking cessation and relapse. Among others, the psychoactive effects 
of nicotine, associative learning processes, environmental culture (including access 
to and availability of tobacco products, acceptability, and parental or peer modeling), 
individual characteristics (ie, genetic and personality features),7 and heritability (twin 
studies suggest a genetic contribution of about 50% in the prevalence of cigarette 
smoking, the ability to quit smoking, and the number of cigarettes smoked per day)8 
seem to contribute to starting and sustaining cigarette consumption. However,  nicotine 
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dependence and the psychological distress experienced while 
quitting are widely recognized as particularly relevant predic-
tors of smoking cessation.
This review describes these two constructs in detail, 
shows how they may affect smoking cessation outcome, 
and highlights the importance of assessing both nicotine 
dependence and psychological distress when assisting smok-
ing patients, in order to provide tailored support during the 
smoking cessation process.
Management of nicotine 
dependence
Current evidence-based guidelines for the treatment of 
nicotine dependence recommend using pharmacotherapy in 
conjunction with counseling.5 However other factors, which 
will be briefly described below, may have clinical implica-
tions that need to be taken into account when assisting a 
smoker in quitting.
Smokers’ socio-demographic 
characteristics
The association between smoking and low socioeconomic 
status (SES) has become stronger in almost all industrial-
ized countries9–13 despite the introduction of anti-tobacco 
interventions.14,15
A growing literature is focused on the role of socio-
demographic variables as factors influencing the probability 
of quitting. Quitting smoking seems more likely among 
better-educated subjects,16–19 less disadvantaged socioeco-
nomic groups,17–20 older individuals,19,21 and users living with 
a spouse or partner.18–20
A possible explanation of these results is that better-
educated individuals seem to be more responsive to messages 
about the adverse consequences of smoking compared with 
poorly-educated ones. Moreover, lower-SES smokers seem 
to have a lower level of social support and confidence in their 
ability to quit.22 Finally, lower-SES women often perceive 
smoking as an effective strategy for coping with stress and 
difficult living circumstances.23,24
Older people have higher success rates due to their greater 
likelihood of adhering to a treatment program, smaller risk 
of relapse, and a higher incidence of tobacco-related health 
problems.25
When marital status is considered, quitting seems to be 
an easier task for married than for nonmarried subjects. The 
literature suggests that married subjects, especially men, have 
an overall better adherence to treatments.26,27
Pathophysiology of nicotine dependence
Inhaled nicotine reaches the brain rapidly, about 10–20  seconds 
after a puff, and has an elimination half-life in chronic 
 smokers of about 2 hours. As a consequence, nicotine blood 
levels are stable only if subjects smoke frequently.28
Nicotine stimulates the central nicotinic cholinergic 
receptors inducing the release of several neurotransmitters 
in the brain. Dopamine, mainly produced in the ventral 
 tegmental area and in the nucleus accumbens, is of  particular 
importance since it provokes a pleasurable experience 
which promotes the reinforcing self-administration of 
nicotine. Other neurotransmitters, including norepinephrine, 
 acetylcholine, serotonin, γ-aminobutyric acid (GABA), 
 glutamate, and endorphins lead to the arousal, mood modula-
tion,  performance enhancement, analgesic, and weight-loss 
effects associated with smoking.
With repeated exposure to nicotine, neuroadaptation 
( tolerance) develops,29 while nicotine-mediated desensitiza-
tion of receptors leads to upregulation of receptors in the brain. 
Chronic smokers experience symptoms of craving and with-
drawal when desensitized nicotinic receptors become newly 
responsive during periods of abstinence, such as night-time 
sleep. Thus, smokers modulate their smoking habit through-
out the day to maintain nicotine plasma levels high enough 
to prevent the occurrence of withdrawal symptoms over the 
night or over the nonsmoking period. Moreover, conditioned 
smoking cues tend to maintain smoking behavior during the 
periods of saturation and desensitization of nicotinic brain 
receptors.29 Over time, associative learning between stimuli 
in the environment (eg, specific moods, situations) and the 
positive rewarding effects of nicotine and withdrawal symp-
toms might occur. Cues begin to control behavior, evoking 
craving for the drug or drug-seeking behavior (for example, 
lighting a cigarette after finishing a meal).
The treatment of nicotine dependence should take into 
account the clinical implications due to the combination of pos-
itive reinforcement, such as enhancement of mood or decrease 
of withdrawal symptoms, along with conditioning. Drugs for 
smoking cessation act primarily on the control of withdrawal 
symptoms but do not replace the positive and pleasant effects 
of smoking. Behavioral counseling should help smokers to 
cope with conditioning. A strong dose-response relationship 
between counseling intensity (length and number of treatment 
sessions) and quitting success has been observed.5
Motivation to quit smoking
Quitting smoking leads to loss of the positive and pleasant 
effects of nicotine and produces the negative symptoms of 
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nicotine withdrawal. In addition, there is an important impact 
on the daily habits of the abstinent smoker since smoking is 
associated with a variety of learned and social behaviors. For 
these reasons, nicotine dependence can be viewed as a state 
in which the personal cost of quitting can be extremely high 
(ie, too uncomfortable or impairing personal functioning too 
greatly).30 Whether a smoker succeeds in quitting depends 
on the balance between that individual’s motivation to stop 
smoking (ie, expected benefits of smoking cessation) and the 
degree of nicotine dependence.
According to the trans theoretical model,31 smokers who 
prepare their attempts to stop well in advance increase their 
chances of success.32 Thus, in an assisted smoking-cessation 
program the motivation to quit should be the prerequisite to 
engage in a smoking cessation attempt. However, in smokers 
suffering from smoking-related diseases, for whom quitting 
is a priority, a more interventional approach, aimed at least 
at smoking reduction, has been suggested.33 A meta-analysis 
based on results from randomized controlled clinical trials 
on motivational interviewing for smoking cessation vs brief 
advice or usual care yielded a modest but significant increase 
in quitting rates.34
Smokers’ motives for quitting seem also to reflect a 
social unacceptability of smoking which has been buttressed 
by measures intended to reduce tobacco use. For instance, 
by alerting people to the dangers of second-hand smoke, 
health campaigns might be responsible for smokers feel-
ing uncomfortable about smoking in public.35,36 Moreover, 
nonsmokers may tend to see smokers as drug addicts whose 
habit threatens their health and that of others.37 International 
literature reports evidence that the denormalization of smok-
ing is an effective component of measures intended to reduce 
tobacco use.35,36,38 For instance, a longitudinal study assessing 
data from Canada, USA, UK, and Australia concluded that 
smokers are more likely to intend to quit and to be abstinent 
at follow-up when they have important social denormaliza-
tion beliefs about smoking, such as feeling disapproved of 
for smoking, being uncomfortable about smoking in public, 
and being advised to quit by people close to them.36
Motivation seems also strictly linked to the perception 
of self. For instance, most teenagers regard themselves as 
smokers but few think they are addicted and, although many 
are interested in quitting, they usually do not consider this a 
priority.39 The barriers to quitting frequently revolve, at least 
in teenagers, around social image. Smoking is viewed as a 
social behavior and an important mechanism for sustaining 
and reinforcing social bonds. Being with smoking friends 
reinforces smoking and has a negative impact on attempts to 
quit. Thus, this subgroup of smokers seem to be reluctant to 
take up traditional cessation services and rather need to be 
grounded in their understanding of smoking and the social 
factors which support smoking in addition to being helped to 
understand how support may increase quitting success.39
Response to pharmacotherapy
Despite pharmacological treatments that have been found 
effective in controlled clinical trials, estimated abstinence 
rates at 6 months range from 19% to 33% depending on 
the drug used,5 and are expected to be lower in unselected 
populations (ie, real life situations).
Large inter-individual variability in drug response may be 
caused by low adherence to the treatment, drug interactions, 
changes in the rate of nicotine metabolism and the smoker’s 
genetic make-up. Adherence to pharmacotherapy for smok-
ing cessation has been demonstrated to be highly correlated 
with improved tobacco abstinence.40 Drug interaction is a 
preventable cause of inter-individual variability in nicotine 
metabolism. CYP2A6-metabolized drugs may affect nico-
tine pharmacokinetics and efficacy of nicotine replacement 
therapy.8 Changes in nicotine metabolism may depend on 
 physiological influences (such as age and gender) and patho-
logical conditions (eg, CYP2A6 activity is reduced in patients 
with alcoholic liver disease and viral hepatitis).28 Finally, the 
pharmacotherapy of smoking cessation is affected by the 
interplay of several gene products that influence the pharma-
cokinetics and pharmacodynamics of medications, including 
inherited differences in drug targets (eg, nicotine and dopamine 
receptor subtypes) and drug disposition (eg, metabolizing 
enzymes including CYP2A6 and CYP2B6).41 Variants in the 
dopamine D2 receptor have been reported to affect response to 
transdermal nicotine and/or bupropion. Variation in the opiate 
mu 1 receptor gene seems to influence response to transdermal 
nicotine, and variants in the CYP2B6 gene have been found 
to predict response to  bupropion.8 Genetically low metaboliz-
ers (including people with variant CYP2A6 genes associated 
with substantially reduced enzyme activity) smoke on average 
fewer cigarettes per day, appear to be less dependent, and are 
more likely to quit.8
An algorithm and guide based on the opinion of experts in 
tobacco cessation has been recently developed42 and genetic 
variations to be considered in order to personalize nicotine 
dependence pharmacotherapy have been discussed.41
Psychiatric comorbidity
According to population-based data, more than 40% of smok-
ers report a current psychiatric disorder and 60% a lifetime 
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one.43 Nicotine may serve to medicate some psychiatric 
symptoms.8 For example, since smoking inhibits monoamine 
oxidases, the release of serotonin and norepinephrine induced 
by nicotine is similar to the one occurring under treatment 
with monoamine oxidase inhibitor antidepressants.
Based on results from meta-analyses, the therapies effec-
tive in treating nicotine dependence in the general population 
also work in patients with severe mental illnesses and do 
not worsen their mental state if they have stable psychiatric 
conditions.44
In this framework, the presence of psychiatric comorbid-
ity should always be assessed when treating nicotine depen-
dence, because of its implications in the psychological or 
pharmacological support needed to complement the assisted 
smoking cessation program.
Treatment of nicotine dependence
Treatment is targeted towards dealing with physical addiction 
to nicotine, psychological reliance on the effects of nicotine, 
and behavioral aspects of tobacco use. Several pharmacologi-
cal and nonpharmacological interventions are effective in 
treating nicotine dependence and evidence-based guidelines 
have been developed.5
Nonpharmacological approaches include educational, 
motivational, or behavioral interventions and may be tai-
lored to different populations. In general, intensive support 
increases the likelihood of quitting; for instance, the 3%–5% 
1-year spontaneous quit rate improves to 7.5% with brief phy-
sician advice.45 Similarly, behavioral support increases quit 
rates when it is given via telephone quit lines,46 or group47 or 
individual counseling.48 Finally, a combination of counseling 
and medication is more effective for smoking cessation than 
either medication or counseling alone.5
Pharmacological aids are recommended for all smokers 
trying to quit, except when medically contraindicated or 
in cases where there is insufficient evidence of effective-
ness (eg, pregnant women, smokeless tobacco users, light 
 smokers, adolescents).5 They are currently classified as 
first-line (bupropion, nicotine, varenicline) and second-line 
 medications (nortriptyline, clonidine).5 First-line medications 
are safe and effective and have been approved by the US Food 
and Drug Administration (FDA) for the treatment of nicotine 
dependence. Weaker evidence of efficacy has been found 
for the second-line medications. Several concerns still exist 
about their side effects and they have not yet received FDA 
approval as treatments for nicotine dependence (mechanisms 
of action, common side effects, and cautions are reported 
in Table 1).
In clinical trials, nicotine replacement therapy and bupro-
pion approximately double quit rates,49,50 whereas vareni-
cline increases quit rates by three-fold over those achieved 
with placebo.51 Looking at second-line drugs, nortriptyline 
doubles the odds of quitting.50 Clonidine, although associated 
with increased smoking cessation, shows lower odds.52
Although pharmacotherapies are able to improve success 
rates, the probability of maintaining abstinence 1 year after 
smoking cessation still remains fairly low (overall 20%).45 
For this reason, new drugs are being tested.53 The first is 
the nicotine vaccine, which stimulates the immune system 
to develop anti-nicotine antibodies. Preliminary studies in 
humans show that it is safe and well tolerated.54 Another 
interesting drug is a selective cannabinoid CB1 receptor 
antagonist, rimonabant, which restores the balance of the 
endocannabinoid system. It increases the chance of quitting 
by approximately 1.5-fold, but evidence on its capacity to 
maintain abstinence is still inconclusive. Further cannabinoid 
receptor antagonists are under study.55
Pharmacotherapies appear effective and cost-effective, 
however research on their appropriate use in unselected 
populations (ie, different from those usually participating 
in randomized clinical trials) is warranted to increase their 
applicability and effectiveness in daily clinical practice.53 
Similarly, further research is needed to find treatments effec-
tive in specific subpopulations of smokers. For instance, in 
the past, it was suggested that subjects high in pretreatment 
negative affect respond best to support counseling; those low 
in pretreatment negative affect respond best to skills training; 
while self-reports of pretreatment craving predicted response 
to the nicotine replacement treatment.56
Psychological distress as a predictor 
of smoking cessation
Psychological distress is a nonspecific dimension which refers 
both to symptoms and also to normal emotional responses to 
adversity. It encompasses sadness, frustration, anxiety, and a 
number of other negative mood states, such as hopelessness, 
nervousness, and depressive mood.  Psychological distress 
can range from mild to severe and from transient to persis-
tent.57 Healthy subjects facing changes in their life58 as well as 
patients with organic or psychiatric disorders may experience 
it,59,60 as can smokers at the initiation, maintenance, quitting, 
or relapse stages.61
Affective states, such as irritability, anxiety, and depres-
sion, might be due either to the fact that the subject is facing 
a challenge such as quitting smoking, or to nicotine interrup-
tion. For this reason, a careful differential diagnosis should be 
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Table 1 Pharmacotherapies for nicotine dependence
Site of action/ 
mechanisms of action
Side effects Cautions
First-line therapies
Nicotine replacement therapy  
(patch, gum, inhaler, nasal  
spray, lozenge, microtab)
Receptor stimulation/agonist  
of nicotine receptors, nicotine  
substitution
Localized irritation: skin  
irritation (patch); mouth  
and throat irritation  
(oral preparations)
Recent myocardial infarction,  
serious arrhythmias, unstable  
angina pectoris; hyperthyroidism,  
pheochromocytoma;  
uncontrolled hypertension;  
peptic ulcers; allergy to tape  
or dermatological conditions
varenicline Receptor stimulation/α4β2  
neuronal nicotinic cholinergic  
receptors partial agonist
Nausea, headache, abnormal  
dreams
Severe renal impairment;  
history/presence of major  
depression; impair ability  
to drive; pregnancy
Sustained-release bupropion Dopamine transporter/inhibition  
of neuronal re-uptake  
of noradrenaline and dopamine,  
with minimal effect on the  
re-uptake of serotonin
insomnia, dry mouth,  
headache
Seizure disorders; bulimia  
or anorexia nervosa, bipolar  
disorder; severe hepatic  
necrosis; concomitant/recent  
use of monoamine oxidase  
inhibitors
Second-line therapies
Nortriptyline Serotonin transporter/serotonin  
and noradrenalin re-uptake  
inhibition
Dry mouth, blurred vision, 
constipation, urinary retention, 
sedation, drowsiness,  
weight gain, orthostatic  
hypotension
Cardiovascular disease;  
pregnancy
Clonidine Other nervous  
pathways/α2-noradrenergic  
agonist
Dry mouth, drowsiness,  
dizziness, sedation, constipation,  
allergic reactions, bradycardia,  
abnormally high or low blood  
pressure
Cardiovascular disease;  
pregnancy
Other therapies (not yet approved by the FDA)
Nicotine vaccine Nicotine absorption/active  
immunization
Injection site reaction, flu-like  
symptoms, headache, myalgia
To be defined
Rimonabant Other nervous pathways/selective  
antagonist of cannabinoid  
type 1 receptors
Nausea, upper respiratory tract  
infections
Depression and suicidal  
to be defined
always conducted in order to establish whether psychological 
distress is related to the real distress the subject is feeling 
during the cessation program or to the occurrence of nicotine 
withdrawal symptoms. This distinction can be achieved by 
carefully examining symptoms and signs that occur while 
quitting (for example, withdrawal symptoms tend to appear 
in the first week of cessation and usually last 2–4 weeks).
Psychological distress
Several studies investigated psychological distress as a gen-
eral dimension in smokers. Dube et al analyzed data from 
172,938 adult respondents in the 2007 Behavioral Risk Factor 
Surveillance System and observed that smokers and those 
attempting to quit had higher levels of psychological distress 
when compared to those who never smoked.62 Lawrence et al 
examined, among participants in the 2005 United States 
National Health Interview Survey (NHIS), the relationship 
between the outcome of smoking cessation attempts and 
psychological distress. They compared the answers given by 
recent successful quitters (ie, those who reported having quit 
smoking 7–24 months prior to the survey without relapses) 
with those by current smokers (ie, those who had unsuccess-
fully attempted to quit smoking in the previous 12 months). 
The rate of smoking increased with psychological distress 
(from 17.7% to 41.9%) and subjects with high levels of psy-
chological distress were more likely to be current smokers. 
Although they commonly had the intention to quit smoking 
and tried to do it, they had a significantly lower number of 
abstinence periods lasting at least 6 months.63
In a large Australian national household survey, cur-
rent smokers with psychological distress were just as, or 
more likely, to report planning to quit as those without 
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 psychological distress. However, smokers who had past 
 failure in quitting and smoked to feel relaxed or deal with 
stress were more likely to report psychological distress.64
Two clinical studies showed that increases in post-quit 
anger were associated with relapse 5 days65 and 28 days66 after 
quitting; however, in the second study,66 this effect was lost 
when other measures of craving and withdrawal were added 
to the model. Similarly, higher levels of hostility, tension, 
and depressive feelings have been associated with a higher 
risk of continuing smoking.67,68 A more recent study reported 
that those with high trait anger relapsed sooner than their 
low trait anger counterparts.69 Similarly, Patterson et al found 
that smokers with increased anger during the first week of 
treatment relapsed almost twice as quickly as those who did 
not have an increase in post-quit anger symptoms. Moreover, 
participants with increased post-quit anger symptoms took 
significantly fewer days to relapse compared to those who 
did not report increased post-quit anger symptoms (8 days 
vs 54 days, respectively).70
According to our study on 297 cigarette smokers fol-
lowed for 1 year, high levels of psychological distress at 12, 
26, and 52 weeks of follow-up affected long-term smoking 
cessation rates. A possible explanation of this phenomenon 
is that the psychological distress may have implied affec-
tive vulnerability, dysphoria, and negative affectivity, and 
therefore, weakened persistence in a stressful task such as 
quitting smoking.71
Negative affectivity as a dimension  
of psychological distress
Several studies have focused on a more specific  psychological 
dimension contained in the broader construct of psychologi-
cal distress, so-called “negative affectivity,” which mainly 
refers to symptoms of depression and/or anxiety. 
Prospective studies have shown that affective distress at 
the beginning of treatment72 and after quitting73,74 predicts 
poor outcome. Furthermore, in retrospective studies, smokers 
consistently report that relapse to smoking often occurs in 
situations involving negative moods such as anxiety, anger, 
and depression,75–78 and that smokers who smoke more 
frequently in negative affect situations are more likely to 
relapse.79 Moreover, Shiffman and Waters found that surges 
in  negative affect often began a few hours before a smoking 
relapse occurred.80 Thus, it may be the responses to acute 
stressors and resulting rapidly increasing negative affect 
that are most relevant to relapse. Finally, changes in  negative 
affectivity seem consistently related to the persistence of the 
urge to smoke.81
Interesting evidence emerges from studies conducted 
on smokers applying to smoking cessation clinics. 
 Fakhfakh et al82 observed that 22.9% of them had depres-
sion, 20% anxiety, and 7.1% had symptoms of both anxiety 
and depression.
According to our experience, smokers who ask for a 
baseline evaluation at a smoking cessation facility report 
higher levels of negative affectivity than smokers from the 
general population, considering symptoms of both anxiety 
and depression. A possible explanation for this relationship 
might be that anxiety and depression can act as important 
motivators to quit.83
Further contributions come from longitudinal surveys. 
Shiffman et al compared reports of immediate experiences 
during random moments, highly tempting situations, and 
first relapses to smoking in a sample of quitters. A linear 
relationship was found between the type of assessment and 
negative affect ratings. First relapses were characterized by 
high negative affect, temptations involved somewhat less 
negative affect, and random moments were characterized by 
the lowest negative affect ratings. Moreover, approximately 
20% of first relapses to smoking occurred at moments when 
negative affect was extremely high (approximately 2.5 SD 
above the mean).84
Niaura and colleagues prospectively examined the abil-
ity of current symptoms of depression to predict failure to 
quit smoking in treatment-motivated smokers. Pretreatment 
depressed mood was assessed by three different methods in 
three separate samples, two of which comprised smokers 
receiving combined pharmacological and behavioral treat-
ments and a third in which smokers received self-help mate-
rials only. Interestingly, even very low levels of depressive 
symptomatology at the outset of a smoking cessation attempt 
predicted dramatically lower long-term abstinence rates.85
Finally, Kahler et al examined the within-person covaria-
tion between smoking abstinence and depressive symptoms 
following a quitting attempt. Although in the first weeks all 
the subjects reported a slight increase of depressive symp-
toms, there was an inverse relationship between time-varying 
abstinence from smoking and concurrent level of depres-
sive symptoms. This means that passing from smoking to 
abstinence was associated with a reduction in depressive 
symptoms. Subjects abstinent at all follow-up visits (2, 8, 
16, 26 weeks) had lower levels of depressive symptoms as 
measured at baseline and maintained such levels throughout 
the follow-up observation. Smokers who relapsed showed the 
lowest levels of depressive symptoms when abstinent while 
those who continued to smoke had a gradual increase over 
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time.86 Thus, according to this study, depressive symptoms 
may have a positive influence in pursuing a task such as 
quitting.
Different conclusions can be drawn when considering 
anxiety. In a longitudinal study conducted on 575 women 
and examining predictors of smoking cessation, high lev-
els of anxiety significantly predicted subsequent quitting. 
Women more anxious at baseline were about three times 
more likely to report quitting 13 years later than women with 
low baseline anxiety.87
Distress tolerance
It has become increasingly clear that relapses to smoking may 
occur very early in many cessation attempts, ie, within hours 
or days after the quit day. For example, in studies of people 
who quit on their own, approximately one-third to one-half 
smoke within a few days and 50%–60% smoke within the first 
2 weeks.88–90 Early relapse is also common among participants 
who receive smoking cessation treatments. In studies examin-
ing nicotine replacement strategies or group-based cessation 
intervention, 43%–50% of participants still smoked within 
the first week91 and most of the relapses occurred within the 
first few days.81,92 Not only are early relapses common, but 
the vast majority of smokers who experience them ultimately 
do not succeed in quitting. In studies following self-quitters 
and in those using nicotine replacement, it is estimated that 
more than 85% of participants who experienced an early 
relapse subsequently failed to quit.91,93
Emerging evidence suggests that it is not just the 
severity or intensity of nicotine withdrawal, but also how 
an individual responds to discomfort and distress that 
predicts early smoking relapses. In this framework, the 
term “distress tolerance” has been coined to convey a 
behavioral tendency to continue to pursue a goal despite 
encountering various states of affective discomfort, which 
may be in response to perceived physical and/or psycho-
logical distress.94
Whereas many smokers quit smoking successfully despite 
high levels of discomfort, it is likely that a low threshold for 
tolerating such unavoidable distress would be associated with 
increased difficulty in quitting. Brown et al studied current 
smokers who by quit attempt history were either immedi-
ate (ie, had never quit for more than 24 hours) or delayed 
relapsers (ie, had quit for at least 3 months) and assessed 
individuals’ distress tolerance, as indexed by their persistence 
on psychological and physical challenge tasks.94 The results 
indicated that immediate relapsers were more likely to ter-
minate the challenge tasks than delayed relapsers.
Baker and co-workers stressed the role of low 
 psychological distress tolerance in favoring early relapses, 
hypothesizing that negative affect is the “motivational core” 
of the withdrawal syndrome. They suggested that when 
either stressors or abstinence cause negative affect to grow 
and enter consciousness, increasing negative affect biases 
information processing in ways that promote renewed drug 
administration.95 Brown et al agreed with this model and 
further posited that there are individual differences in how 
smokers respond to negative affect, and it is these responses 
in the face of negative affect that determine who relapses in 
a few days/hours and who maintains abstinence.96
Patient-focused perspectives  
in quitting smoking
The current Clinical Practice Guidelines5 recommend 
addressing patients’ smoking at each visit using a five-
step strategy called the 5As: ask about tobacco use; advise 
smokers to quit; assess smokers’ willingness to make a quit 
attempt; assist with treatment; arrange follow-up. Although 
some authors report concerns related to the overuse of 
tobacco cessation advice,97,98 Conroy et al demonstrated a 
strong association between the full range of 5A tobacco 
counseling steps and satisfaction with overall health care as 
well as tobacco-related care.99
Advice, to be really effective, should be given within 
the framework of a good patient–clinician relationship, in 
which clinicians take into account patients’ perspectives 
about treatment and smoking cessation. For instance, Butler 
et al reported that most subjects consider it good practice to 
use a respectful tone; sensitivity to the patient’s receptivity; 
understanding the patient as an individual; being supportive; 
and not preaching.100 Moreover, it has been observed that 
advice/procedures offered regarding quitting may either 
enable or discourage the uptake of smoking cessation ser-
vices in subjects sensible to the problem, such as pregnant 
women smokers.101
When smokers ask for help to quit, they also have a set 
of beliefs about the psychological benefits of smoking (eg, to 
cope with their negative affect), the health risks associated 
with smoking (eg, health risks are underestimated while the 
ability to minimize those risks is overemphasized),102 as well 
as the pros and cons of smoking cessation. During cessation 
attempts, they may change their beliefs, imagining less psy-
chological benefits and more health threats due to smoking. 
These changes predict success in quitting: those who relapse 
report beliefs similar to current smokers with a decrease of 
their beliefs about the health risks of smoking.103 Thus, it seems 
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appropriate to encourage such changes in the early stages of 
treatment as well as managing them in case of relapse, to 
prevent the impairment of future attempts to quit.
Patients’ beliefs can also be modulated by the evidence of 
positive changes produced by smoking cessation. For instance, 
abstainers often have the perception of better functioning and 
well-being. In a longitudinal study comparing subjects randomly 
assigned to varenicline, bupropion, or placebo, those treated 
with active treatments (varenicline more than bupropion) had 
significantly improved health-related quality of life and self-
control compared with those who received placebo.39
The direct result of taking into account patients’ perspec-
tive and beliefs in the framework of a proper clinician–patient 
relationship is adherence, the main ingredient for achieving 
treatment goals. In a study on pregnant smokers helped to quit 
with nicotine replacement therapy, adherence was a strong 
predictor of cessation.104 Similarly, in a study among Chinese 
smokers the quit rate in the adherent group was significantly 
greater (40%) than that in the nonadherent one (25%).105
Conclusion
Persistent cigarette consumption seems to be strongly influ-
enced by two complex factors: nicotine dependence and psy-
chological distress. While the level of nicotine dependence is 
commonly measured in smokers attending smoking cessation 
programs, the assessment of psychological distress is often 
neglected. However, such an evaluation should be performed, 
to get a complete picture of the smoker and offer a tailored 
intervention. Some patients, for instance, might benefit from 
psychological support aimed at managing psychological 
distress, a high level of negative affectivity, or a low psycho-
logical distress tolerance experienced while quitting.
The framework in which assessment, treatment, and advice 
should be delivered is a good patient–clinician relationship, 
which should take into account patients’ perspectives, beliefs, 
and expectations about treatment and smoking cessation.
The desired outcome is to acquire the motivation to quit, 
and to adhere to treatment, which respectively provides the 
prerequisite for starting a smoking cessation attempt, and the 
main way to achieve treatment goals.
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